Well Referenced

Tag: neoadjuvant therapy

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

This 2021 randomized pilot trial compared neoadjuvant everolimus plus letrozole (NET) with standard chemotherapy (FEC) in 40 postmenopausal women with ER-positive, HER2-negative breast cancer. The NET arm demonstrated a higher ultrasound response rate (65% vs. 40%) and better treatment completion (90% vs. 70%) compared to the FEC arm. Additionally, NET

Read More »
June 26, 2025 No Comments

Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study

This prospective single-arm “window of opportunity” trial evaluated the biological effects of short-term metformin administration in 39 non-diabetic women with early-stage breast cancer. Patients received 500 mg of metformin three times daily for at least two weeks between diagnostic biopsy and surgery. Metformin treatment led to significant reductions in tumor

Read More »
June 26, 2025 No Comments